shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
30 March 2023Big PharmaLiz Hockley

GSK signs licence deals with three generics firms to make HIV preventative for low income countries

The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.
Big Pharma
1 June 2022   GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

More on this story

Big Pharma
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.
Big Pharma
1 June 2022   GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

More on this story

Big Pharma
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.
Big Pharma
1 June 2022   GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.